{
    "nct_id": "NCT03442556",
    "official_title": "PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency",
    "inclusion_criteria": "* Signed informed consent form (ICF) providing agreement to adhere to the dosing schedule, report for all trial visits and authorization, use and release of health and research trial information\n* Histologically or cytologically confirmed adenocarcinoma of the prostate (excluding predominant small cell histology)\n* Ongoing gonadal androgen deprivation therapy with gonadotropin-releasing hormone (GnRH) analogues, antagonists or orchiectomy; patients who have not had an orchiectomy must be maintained on effective GnRH analogue/antagonist therapy\n* Castration resistant prostate cancer as defined by serum testosterone < 50 ng/ml and PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions at least 1 week apart\n* Presence of metastatic disease on bone or computed tomography (CT) scan\n\n  * Evaluable disease progression by modified RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)\n  * Bone disease on bone scan\n* Prior therapy with sipuleucel-T, abiraterone, enzalutamide, docetaxel, and/or cabazitaxel; there is no limit to the number of prior treatment regimens in the castration resistant setting, so long as prior therapy does not include platinum chemotherapy or a PARP inhibitor; prior platinum chemotherapy in the hormone sensitive setting is permitted, so long as it has been at least 6 months since last dose\n* Eastern Cooperative Oncology Group (ECOG) performance status of =< 1\n* Life expectancy >= 12 weeks\n* No prior malignancy is allowed except:\n\n  * Adequately treated basal cell or squamous cell skin cancer or\n  * In situ carcinoma of any site or\n  * Other adequately treated malignancy for which the patient has been disease-free for at least one year (any prior chemotherapy is allowed)\n* Documented evidence of at least ONE or MORE of the following:\n\n  * Pathogenic mutation or inactivating alteration of a gene involved in homologous recombination repair in the tumor\n  * Note, that if this alteration is identified in a circulating tumor deoxyribonucleic acid (ctDNA) assay, the variant-allele fraction must be > 20% to indicate relevance to predominant tumor clone\n\n    * Mutation in one or more other genes involved in homologous DNA recombination repair in the tumor may be included at investigator's discretion\n    * Homologous recombination repair deficiency by genomic signature in the tumor by BROCA-HR, Foundation One or equivalent assay\n    * Presence of pathogenic or likely pathogenic germline mutation/variant in BRCA2, BRCA1, ATM or PALB2\n  * Note: Germline mutations in other HR genes will be considered at investigator's discretion)\n* Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (within 14 days of first dose of study drug)\n* Platelets > 100 x 10^9/L (within 14 days of first dose of study drug)\n* Hemoglobin >= 9 g/dL (within 14 days of first dose of study drug)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN; if liver metastases, then =< 5 x ULN (within 14 days of first dose of study drug)\n* Bilirubin =< 1.5 x ULN (< 2 x ULN if hyperbilirubinemia is due to Gilbert's syndrome) (within 14 days of first dose of study drug)\n* Serum creatinine =< 1.5 x ULN or estimated glomerular filtration rate (GFR) >= 45 mL/min using the Cockcroft Gault formula (within 14 days of first dose of study drug)\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Currently receiving active therapy for other neoplastic disorders\n* Symptomatic and/or untreated central nervous system (CNS) metastases; patients with asymptomatic previously treated CNS metastases are eligible provided they have been clinically stable for at least 4 weeks\n* Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, active or symptomatic viral hepatitis or chronic liver disease\n* Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease or cardiac ejection fraction measurement of < 35 % at baseline\n* Treatment with an investigational therapeutic drug within 30 days of cycle 1\n* Prior therapy with a PARP inhibitor (e.g., olaparib, talazoparib, veliparib, niraparib, rucaparib)\n* Prior therapy with a platinum chemotherapy (e.g. cisplatin, carboplatin, oxaliplatin) in the castration resistant setting; (prior platinum chemotherapy in the hormone sensitive setting is permitted, so long as time since last dose is 6 months or greater)\n* Active, ongoing toxicity (Common Terminology Criteria for Adverse Events [CTCAE] grade 2 or higher) from prior therapy\n* Presence of dementia, psychiatric illness, and/or social situations limiting compliance with study requirements or understanding and/or giving of informed consent\n* Pre-existing duodenal stent and/ or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib\n* Any condition(s), medical or otherwise, which, in the opinion of the investigators, would jeopardize either the patient or the integrity of the data obtained",
    "miscellaneous_criteria": ""
}